Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.69B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.28M
Average 1.16M
Income Statement
Follow revenue through to earnings.
Revenue
$7.50M
FY 2025 · Annual
Operating Income
-$373.07M
FY 2025 · Annual
Net Income
-$345.91M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.44M | 9.43M | 0 | 0 | 7.5M |
| Cost of Revenue | 0 | 0 | 167.51M | 2.56M | 2.54M |
| Gross Profit | 18.44M | 9.43M | (167.51M) | (2.56M) | 4.96M |
| Gross Margin | 100.0% | 100.0% | — | — | 66.1% |
| Research & Development | 75.46M | 105.77M | 167.51M | 210.39M | 300.94M |
| Selling, General & Admin | 21.97M | 32.81M | 46.54M | 68.9M | 79.63M |
| Operating Expenses | 97.43M | 138.58M | 46.54M | 276.74M | 378.03M |
| Depreciation & Amortization | 906K | 1.41M | 3.54M | 2.56M | 2.54M |
| EBITDA | (78.09M) | (127.74M) | (210.51M) | (235.86M) | (342.35M) |
| EBITDA Margin | -423.5% | -1354.0% | — | — | -4564.7% |
| Operating Income | (78.99M) | (129.14M) | (214.05M) | (279.3M) | (373.07M) |
| Operating Margin | -428.4% | -1368.9% | — | — | -4974.3% |
| Interest Income | 466K | 8.71M | 27.62M | 41.94M | 26.83M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 105K | 3.89M | 31.37M | 40.88M | 28.18M |
| Income Before Tax | (78.89M) | (125.26M) | (182.69M) | (238.42M) | (344.89M) |
| Pre-Tax Margin | -427.9% | -1327.7% | — | — | -4598.6% |
| Income Tax Expense | (6K) | 118K | (292K) | (4.09M) | 1.02M |
| Net Income | (78.88M) | (125.37M) | (182.39M) | (234.33M) | (345.91M) |
| Net Margin | -427.8% | -1328.9% | — | — | -4612.1% |
| EPS (Basic) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| EPS (Diluted) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| 43.63M | 60.54M | 66.89M | 77.89M | 79.25M | |
| 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
XENE Earnings Waterfall · TTM
NASDAQ:XENE · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$428.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.70, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| S-8 | S-8 filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G | SC 13G filing | Nov 6, 2026 |
How much revenue does XENE generate?
Xenon Pharmaceuticals Inc. (XENE) reported $7.50M of revenue in fiscal 2025.
Is XENE profitable?
Xenon Pharmaceuticals Inc. (XENE) reported -$345.91M of net income, with a net margin of -4612.1%.
Continue the stock analysis
Jump to another research area for this company.